MedPath

Quadratus Lumborum Block Type III Versus Type II Versus Transversus Abdominis Plane Block in Cesarean Section

Not Applicable
Completed
Conditions
Quadratus Lumborum Block
Cesarean Section
Transversus Abdominis Plane Block
Interventions
Procedure: Quadratus lumborum block typen II
Procedure: Transversus abdominis plane block
Procedure: Quadratus lumborum block III
Registration Number
NCT05950568
Lead Sponsor
The General Authority for Teaching Hospitals and Institutes
Brief Summary

Compare the type III and type II quadratus lumborum block (QLB) to transversus abdominis plane block (TAPB) regarding efficacy in CS

Detailed Description

The transversus abdominis plane block (TAPB) is administered between the internal oblique muscle and the transversus abdominis muscle in the fascial plane, directly pointing to the somatic nerves T6-L1 that run in this plane. In addition, meta-analyses demonstrate that it is an effective analgesic for somatic pain and diminishes opiate intake. It has been reported that TAPB is an efficient analgesic approach following cesarean section .

The quadratus lumborum (QL) muscle block (QLB) is a fascial plane block as local anesthetic (LA) is introduced nearby to the QL muscle to numb the thoracolumbar nerves. QLB is categorized into four types according to drug administration location, I (lateral), II (posterior), III (anterior/transmuscular), and Intravenous, (intramuscular). QLB can effectively decrease both visceral and somatic pain by LA distribution to the thoracic paravertebral space (TPVS), as this block ensures effective pain control from the T7 to L1 dermatomes. QLB is one of the regional techniques that provides the greatest benefit in post-CS pain control, as it is progressively applied in obstetric anesthetic precise to improve analgesic results.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
60
Inclusion Criteria
  • American Society of Anesthesiologists (ASA) physical status II
  • aged 18 to 40 years old
  • presenting for elective Cesarean section
Exclusion Criteria
  • body mass index (BMI) ≥40 kg/m2
  • weight < 50kg
  • height < 150 cm
  • contraindications for the use of active labor, spinal anesthesia
  • recent opiate intake
  • hypersensitivity to any used medication
  • substantial cardiovascular diseases
  • renal diseases
  • hepatic, diseases.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Quadratus lumborum block type IIQuadratus lumborum block typen IIA 22 gauge needle was positioned between the erector spinae muscle in the thoracolumbar fascia's middle layer
Transversus abdominis plane blockTransversus abdominis plane blockA 22 gauge needle was positioned between the internal oblique and transversus abdominis muscles
Quadratus lumborum block type IIIQuadratus lumborum block IIIA 22 gauge needle was positioned between the psoas and quadratus lumborum muscles at the anterior fascia lumbosacral
Primary Outcome Measures
NameTimeMethod
Total postoperative consumed pethidine24 hour postoperatively

Numerical rating scales (NRS) score was evaluated at Post Anesthesia Care Unit (PACU), 2, 4, 6, 8, 12, 18, and 24 hours as as 0 is no pain and 10 is the worst pain imaginable. If the NRS score remained ≥ 4, we provided a bolus pethidine (0.5 mg/kg intravenous) and repeatable after 30 minutes if NRS remains≥ 4.

Secondary Outcome Measures
NameTimeMethod
Time of the first analgesic request24 hour postoperatively

If the Numerical rating scales (NRS) score remained ≥ 4, we provided a bolus pethidine (0.5 mg/kg intravenous).

Patient satisfaction24 hour postoperatively

The level of patient satisfaction was graded on a 5-point Likert scale as 0= extremely dissatisfied, 1= dissatisfied, 2= neither satisfied nor dissatisfied, 3= satisfied, 4= extremely satisfied

The degree of postoperative pain24 hour postoperatively

Numerical rating scales (NRS ) score was evaluated at Post Anesthesia Care Unit (PACU), 2, 4, 6, 8, 12, 18, and 24 hours as as 0 is no pain and 10 is the worst pain imaginable.

Trial Locations

Locations (1)

The General Authority for Teaching Hospitals and Institutes

🇪🇬

Cairo, Egypt

© Copyright 2025. All Rights Reserved by MedPath